FIELD: medicine.
SUBSTANCE: invention relates to the use of a composition containing human albumin at a concentration of 5% (w/v) to 25% (w/v) for the treatment of mild and moderate Alzheimer's disease by small volume plasmapheresis. The use of a composition containing human albumin at a concentration of 5% (w/v) to 25% (w/v) for the treatment of mild to moderate Alzheimer's disease (AD) by low volume plasmapheresis (LVPE), wherein the said LVPE regimen includes blood volumes from 600 ml to 900 ml.
EFFECT: above invention improves cognitive function in patients with mild to moderate Alzheimer's disease.
13 cl, 12 dwg
